PCVX Stock Price, Vaxcyte, Inc. Quote, Chart

Market Summary

USD74.58-0.87

Delayed

-1.15%

PCVX Alerts

4 major insider sales recently.

PCVX Stock Price

View Fullscreen

PCVX RSI Chart

PCVX Valuation

Market Cap

8.1B

Price/Earnings (Trailing)

-18.57

Price/Sales (Trailing)

1.7K

Price/Free Cashflow

-19.12

PCVX Price/Sales (Trailing)

PCVX Profitability

Return on Equity

-22.02%

Return on Assets

-20.89%

Free Cashflow Yield

-5.23%

PCVX Fundamentals

PCVX Revenue

Revenue (TTM)

4.8M

Rev. Growth (Yr)

-99.3%

Rev. Growth (Qtr)

-99.6%

PCVX Earnings

Earnings (TTM)

-436.8M

Earnings Growth (Yr)

-57.16%

Earnings Growth (Qtr)

47.44%

Breaking Down PCVX Revenue

Last 7 days

14.4%

Last 30 days

19.5%

Last 90 days

-0.9%

Trailing 12 Months

53.4%

How does PCVX drawdown profile look like?

PCVX Financial Health

Current Ratio

17.42

PCVX Investor Care

Shares Dilution (1Y)

16.10%

Diluted EPS (TTM)

-4.29

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	2.4M	4.2M	5.7M	4.8M
2022	1.7M	2.1M	1.9M	1.9M
2021	0	2.5M	1.8M	1.9M
2020	797.3K	1.4M	1.9M	2.5M
2019	0	0	0	237.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Vaxcyte, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	pickering grant	sold	-161,419	61.7046	-2,616	chief executive officer
May 01, 2024	wassil jim	sold	-184,942	61.6473	-3,000	chief operating officer
May 01, 2024	eydelman mikhail	sold	-102,921	61.7404	-1,667	svp, gen counsel & corp sec
May 01, 2024	eydelman mikhail	acquired	35,690	21.41	1,667	svp, gen counsel & corp sec
Apr 23, 2024	pickering grant	acquired	26,850	1.79	15,000	chief executive officer
Apr 23, 2024	pickering grant	sold	-928,845	61.923	-15,000	chief executive officer
Apr 18, 2024	guggenhime andrew	acquired	42,800	5.35	8,000	president and cfo
Apr 18, 2024	guggenhime andrew	sold	-490,199	61.2749	-8,000	president and cfo
Apr 17, 2024	wassil jim	acquired	18,997	5.35	3,551	chief operating officer
Apr 01, 2024	eydelman mikhail	sold	-111,234	66.7271	-1,667	svp, gen counsel & corp sec

Which funds bought or sold PCVX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	reduced	-77.57	-3,320,240	1,071,240	-%
May 16, 2024	CASTLEARK MANAGEMENT LLC	reduced	-11.99	-228,346	5,125,980	0.21%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	11.78	1,115,910	6,286,300	0.01%
May 16, 2024	Virtus Investment Advisers, Inc.	unchanged	-	17,511	217,089	0.16%
May 16, 2024	Tidal Investments LLC	new	-	404,942	404,942	0.01%
May 16, 2024	COMERICA BANK	added	0.13	1,051,790	12,848,000	0.06%
May 15, 2024	D. E. Shaw & Co., Inc.	reduced	-16.21	-2,439,150	25,086,800	0.02%
May 15, 2024	Royal Bank of Canada	reduced	-88.56	-1,581,000	224,000	-%
May 15, 2024	J. Goldman & Co LP	sold off	-100	-1,111,180	-	-%
May 15, 2024	Alyeska Investment Group, L.P.	sold off	-100	-1,570,000	-	-%

Are Funds Buying or Selling PCVX?

Are funds buying PCVX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PCVX

No. of Funds

PCVX Alerts

4 major insider sales recently.

Unveiling Vaxcyte, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	ra capital management, l.p.	9.99%	9,685,079	SC 13G/A
Feb 13, 2024	janus henderson group plc	7.3%	6,981,376	SC 13G/A
Feb 13, 2024	vanguard group inc	8.88%	8,452,371	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 25, 2024	blackrock inc.	9.0%	8,575,238	SC 13G/A
Feb 14, 2023	ra capital management, l.p.	9.99%	8,153,559	SC 13G/A
Feb 10, 2023	tpg gp a, llc	1.5%	1,190,336	SC 13G/A
Feb 10, 2023	carlyle group inc.	2.6%	2,070,724	SC 13G/A
Feb 10, 2023	janus henderson group plc	7.6%	5,974,139	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A

Recent SEC filings of Vaxcyte, Inc.

View All Filings

Date Filed	Form Type	Document
May 08, 2024	10-Q	Quarterly Report
May 08, 2024	8-K	Current Report
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 03, 2024	4	Insider Trading
May 01, 2024	144	Notice of Insider Sale Intent
May 01, 2024	144	Notice of Insider Sale Intent
May 01, 2024	144	Notice of Insider Sale Intent
Apr 25, 2024	4	Insider Trading
Apr 23, 2024	144	Notice of Insider Sale Intent

Peers (Alternatives to Vaxcyte, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Vaxcyte, Inc. News

Latest updates

Vaxcyte, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4
Revenue	-100.0%	-	7.00	1,640	2,464	654	925	157	690	160	908	299	378	326	787	1,036	329	-
Operating Expenses	-41.8%	114,472	196,676	113,026	87,147	71,192	86,573	58,577	47,886	39,221	29,846	26,951	23,730	19,453	21,308	21,224	27,596	15,837
S&GA Expenses	-100.0%	-	17,527	15,605	14,456	13,112	11,952	10,898	9,417	7,543	6,772	6,523	6,079	4,792	4,898	3,046	3,281	2,456
R&D Expenses	-9.2%	94,587	104,150	97,421	72,691	58,080	51,626	47,679	38,469	31,678	23,074	20,428	17,651	14,661	16,410	18,178	24,315	13,381
Interest Expenses	-	-	-	-	-	-	-	-	2.00	-	-	-	7.00	-	-	-	7.00	7.00
Net Income	47.4%	-95,020	-180,801	-92,664	-68,339	-60,462	-78,050	-57,917	-48,532	-38,986	-28,563	-26,615	-23,679	-20,737	-21,018	-20,320	-27,142	-14,621
Net Income Margin	-8.6%	-91.68*	-84.43*	-52.71*	-63.05*	-100.99*	-115.71*	-90.86*	-69.37*	-67.53*	-52.37*	-51.54*	-34.29*	-	-	-	-	-
Free Cashflow	-22.9%	-164,802	-134,064	-64,887	-60,602	-53,299	-66,368	-39,391	-40,064	-30,622	-52,475	-30,134	-30,888	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	48.5%	2,091	1,408	1,496	1,503	1,008	1,006	412	412	403	324	354	358	382	393	404	416	66.00
Current Assets	38.4%	1,517	1,096	1,295	1,310	841	943	370	364	342	256	303	302	325	389	401	413	62.00
Cash Equivalents	54.1%	613	397	545	531	380	835	279	239	203	70.00	113	152	200	386	397	410	59.00
Net PPE	6.5%	85.00	80.00	11.00	16.00	15.00	10.00	10.00	10.00	10.00	8.00	7.00	6.00	5.00	3.00	3.00	3.00	3.00
Liabilities	-35.9%	107	167	93.00	69.00	63.00	53.00	53.00	45.00	43.00	40.00	48.00	41.00	55.00	47.00	40.00	33.00	12.00
Current Liabilities	-40.1%	87.00	145	86.00	60.00	53.00	41.00	39.00	30.00	27.00	29.00	47.00	41.00	55.00	47.00	40.00	33.00	11.00
Shareholder's Equity	59.9%	1,984	1,240	1,403	1,433	945	954	359	367	360	284	306	317	327	346	364	383	-
Retained Earnings	-10.3%	-1,019	-924	-743	-650	-582	-522	-444	-386	-337	-298	-270	-243	-219	-198	-177	-156	-109
Additional Paid-In Capital	38.6%	3,000	2,165	2,148	2,087	1,527	1,476	804	754	698	583	576	560	547	544	542	540	3.00
Shares Outstanding	14.0%	109	95.00	95.00	94.00	81.00	79.00	62.00	61.00	58.00	52.00	52.00	52.00	-	-	-	-	-
Float	-	-	-	-	4,100	-	-	-	1,100	-	-	-	789	-	-	-	950	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Cashflow From Operations	-23.5%	-159,124	-128,810	-57,548	-62,742	-47,690	-65,221	-38,548	-39,126	-27,702	-51,093	-28,415	-28,680	-13,205	-10,768	-13,055	-9,172	-13,633	-14,406	-9,458	-	-
Share Based Compensation	32.1%	17,629	13,348	13,220	12,544	9,648	7,009	6,648	5,894	4,099	3,158	2,937	2,769	1,865	1,935	1,838	1,289	372	375	265	-	-
Cashflow From Investing	-3139.1%	-451,073	-13,926	22,280	-333,564	-448,101	-35,952	34,706	26,165	49,666	82.00	-18,469	-20,530	-173,391	-722	21.00	-55.00	-349	-953	-60.00	-	-
Cashflow From Financing	29815.8%	818,196	2,735	48,550	546,966	41,562	656,633	44,017	49,878	111,019	8,754	7,599	956	487	555	36.00	264,482	109,797	41,352	368	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PCVX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 94,587	$ 58,080
General and administrative	19,885	13,112
Total operating expenses	114,472	71,192
Loss from operations	(114,472)	(71,192)
Other income (expense), net:
Interest income	21,666	10,393
Grant income	126	654
Realized gains on marketable securities	22	0
Foreign currency transaction losses	(2,362)	(317)
Total other income, net	19,452	10,730
Net loss	$ (95,020)	$ (60,462)
Net loss per share, basic (in dollars per share)	$ (0.85)	$ (0.70)
Net loss per share, diluted (in dollars per share)	$ (0.85)	$ (0.70)
Weighted-average shares outstanding, basic (in shares)	111,690,951	86,206,817
Weighted-average shares outstanding, diluted (in shares)	111,690,951	86,206,817

PCVX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 611,512	$ 397,451
Short-term investments	875,006	682,776
Prepaid expenses and other current assets	30,554	15,727
Total current assets	1,517,072	1,095,954
Property and equipment, net	84,835	79,626
Operating lease right-of-use assets	28,905	30,997
Long-term investments	413,247	162,675
Restricted cash	1,103	1,103
Other assets	46,143	37,562
Total noncurrent assets	574,233	311,963
Total assets	2,091,305	1,407,917
Current liabilities:
Accounts payable	21,717	14,587
Accrued compensation	3,088	11,056
Accrued manufacturing expenses	926	52,767
Accrued expenses	54,171	59,815
Operating lease liabilities — current	7,202	7,113
Total current liabilities	87,104	145,338
Operating lease liabilities — long-term	20,218	22,111
Total liabilities	107,322	167,449
Commitments and contingencies
Stockholders' Equity
Preferred stock, $0.001 par value — 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value — 500,000,000 shares authorized at March 31, 2024 and December 31, 2023; 108,755,731 and 95,364,831 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	112	98
Additional paid-in capital	3,000,394	2,164,583
Accumulated other comprehensive gain	2,889	179
Accumulated deficit	(1,019,412)	(924,392)
Total stockholders' equity	1,983,983	1,240,468
Total liabilities and stockholders' equity	$ 2,091,305	$ 1,407,917

About Vaxcyte, Inc.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

CEO	Mr. Grant E. Pickering M.B.A.
WEBSITE	https://vaxcyte.com
INDUSTRY	Biotechnology
EMPLOYEES	158

Vaxcyte, Inc. Frequently Asked Questions

What is the ticker symbol for Vaxcyte, Inc.? What does PCVX stand for in stocks?

PCVX is the stock ticker symbol of Vaxcyte, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vaxcyte, Inc. (PCVX)?

As of Fri May 17 2024, market cap of Vaxcyte, Inc. is 8.11 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PCVX stock?

You can check PCVX's fair value in chart for subscribers.

What is the fair value of PCVX stock?

You can check PCVX's fair value in chart for subscribers. The fair value of Vaxcyte, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vaxcyte, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PCVX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vaxcyte, Inc. a good stock to buy?

The fair value guage provides a quick view whether PCVX is over valued or under valued. Whether Vaxcyte, Inc. is cheap or expensive depends on the assumptions which impact Vaxcyte, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PCVX.

What is Vaxcyte, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, PCVX's PE ratio (Price to Earnings) is -18.57 and Price to Sales (PS) ratio is 1.7 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PCVX PE ratio will change depending on the future growth rate expectations of investors.